Conoa-B (02162.HK): Spuquipimab injection included in the priority review and approval process for the treatment of chronic sinusitis with nasal polyps

Glonghui, May 23 | Conoa-B (02162.HK) announced that recently, after review by the Drug Evaluation Center (“Drug Evaluation Center”) of the State Drug Administration, it was agreed to include spoximab injections in the priority review process for the treatment of chronic sinusitis with nasal polyps in accordance with the scope of priority review “(1) drugs in short supply, innovative drugs for the prevention and treatment of diseases such as major infectious diseases and rare diseases”. According to reports, spoximab (R&D code CM310) is an efficient, humanized antibody targeting the interleukin 4 receptor alpha subunit (IL-4Rα). It is the first domestically produced and

Gelonghui FinanceMay 23 04:32 ET

[Broker Focus] BOC International is optimistic about the recovery trend of overall investment sentiment in the pharmaceutical industry in 2Q/2H

Jinwu Financial News | BOC International said that recently, the US announced an increase in taxes on low-value consumables such as syringes, ranging from 0% to 50%. Considering that the gross margin of low-value consumables is generally low, the bank believes that a drastic tax increase will reduce the competitiveness of some Chinese products exported to the US market. In terms of sector allocation ideas, the bank is optimistic about the recovery trend of overall investment sentiment in the pharmaceutical industry in 2Q/2H, but the segment may continue to diverge. It is recommended to focus on leaders in major fields such as weight loss/NASH, medical equipment updates, pharmaceutical device innovation going overseas (new technology path/platform), reading significant data on innovative drugs, state-owned enterprise reform+high dividends

金吾財訊May 21 20:39 ET

[Broker Focus] BOC International's first purchase rating for 5 biotech companies indicates that it is firmly optimistic about the sector's potential for heavy snow

Jinwu Financial News | BOC International released an in-depth report on the biotechnology industry. In 2024, the State Council government work report first proposed speeding up the development of the innovative pharmaceutical industry, building new types of productivity such as biomantry, and encouraging entrepreneurship and equity investment. The bank believes that it will continue to introduce supporting policies in the future to promote the development momentum of pharmaceutical innovation. The bank believes that the sector has opportunities for valuation repair within 2024, mainly considering: 1) there has been a large degree of disconnection in the past year, and the bank is optimistic about the chances of Hong Kong stocks recovering compared to US stocks; 2) important overseas events such as overseas licensing/mergers and acquisitions transactions are expected to continue to be implemented in 2024.

金吾財訊May 19 20:36 ET

[Broker Focus] Huayuan Securities first gave Connoya (02162) “buy” rating indicates active promotion of the innovation pipeline

Jinwu Financial News | Huayuan Securities covered Connoya (02162) for the first time. The company was listed on the main board of the Hong Kong Stock Exchange in 2021, focusing on itself and the field of oncology, and efficiently promoting clinical research on a number of innovative products. The core product IL4Rα monoclonal antibody CM310 is expected to be approved for domestic marketing this year. The differentiated layout of other ongoing research and innovation pipelines is progressing smoothly. According to the bank, CM310 is an IL-4Rα monoclonal antibody independently developed by the company. Its new drug marketing application was accepted by CDE in December 2023 and included in priority review, and may become the first domestically produced IL-4Rα monoclonal antibody. Currently IL-4 worldwide

金吾財訊May 6 02:18 ET

Stock prices are falling on the eve of commercialization. When will Conoa-B (02162) remove the mountain Sanofi?

On April 25, Sanofi released its 2024 Q1 financial report. Of its total revenue of 10.464 billion euros, Dipriumab, the core product of the free free pipeline, contributed 2,835 billion euros, equivalent to 21.98 billion yuan. According to the annual report previously disclosed by Sanofi, the total global sales volume of the drug reached 11.5 billion US dollars in 2023. This sales volume is clearly out of reach for the domestic IL4R monoclonal circuit Gemini Conoa-B (02162) and Concord Biotech (CNTB.US), which have yet to commercialize their products. But after years of research and development, Connor, one of the twins

Zhitong FinanceApr 30 02:22 ET

[Broker Focus] GF Securities cuts the target price of Konoah (02162) by 27% to HK$57.73 to maintain the buying rating

Jinwu Financial News | Guangfa Securities released a research report stating that the marketing application for the company's drug CM310, which treats moderate to severe atopic dermatitis in adults, has been accepted by the CDE and included in priority review and approval. At the same time, the company's many self-exempt pipelines are progressing smoothly, and production of some drugs is expected to be reported within the year. According to the bank, the company's revenue in 2023 was 354 million yuan, up 254% year on year, and achieved a net loss of 358 million yuan during the year, mainly due to high R&D expenses (596 million yuan). The company's cash and equivalents, time deposits, and financial assets measured by changes in fair value and recorded as profit and loss were $2,719 billion.

金吾財訊Apr 29 23:41 ET